BD posts healthy global, U.S. Q4 revenues

By The Science Advisory Board staff writers

November 5, 2020 -- Becton Dickinson (BD) has reported worldwide fourth quarter revenues of $4.8 billion (end-September 30), up 4.4% compared to the same period in 2019. U.S. revenues increased 7.4%, to $2.7 billion.

The company's COVID-19 testing sales totaled more than $440 million for the quarter, it said.

Its Life Sciences segment posted revenues of $1.5 billion, up 31.2% compared to the same period last year. However, the company's Medical segment posted worldwide revenues of $2.3 billion, down 4.9% from 2019, and its Interventional segment revenues decreased 3.4% compared to 2019, at $978 million, which BD attributed in part to the impact of COVID-19.

If you like this content, please share it with a colleague!

Related Reading

BD names new executive vice presidents
Becton Dickinson (BD) has appointed Patrick Kaltenbach as executive vice president and chief technology officer. The firm also promoted Dave Hickey to...

BD granted FDA clearance for sample preparation system
Becton Dickinson (BD) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an integrated sample preparation...

BD to provide injection devices for mass doses of COVID-19 vaccines
Becton Dickinson (BD) formed a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines...

BD revenues edge up for 2nd quarter
Becton Dickinson (BD) saw its revenues grow slightly for the second quarter, but the company withdrew its previously issued guidance due to fallout from...